A B S T R A C T Fragment El, a product of plasmic digestion of cross-linked fibrin, binds specifically in vitro to polymerized fibrin but not to fibrinogen. Purified human Fragment El was radiolabeled with 125I or 13'I by the lodogen technique. The uptake of radioiodinated Fragment El in vitro into forming or preformed clots was demonstrated. Animal biodistribution studies of radioiodinated Fragment El showed its rapid removal from the circulation; radioactive catabolites did not reside long in any organ and were excreted in the urine. The uptake in vivo was evaluated in pigs with preexisting venous thrombi of various ages from 1 h up to 5 d at the time of intravenous systemic injection of the tracer. Radioiodinated fibrinogen was also injected into the same animals to compare the uptake of the two tracers. Thrombus-to-blood ratios for Fragment El averaged 43:1 (range 10-108) and 29:1 (range 8-107) in thrombi 1-6 h and 1-5 d old, respectively. In contrast, mean thrombus-to-blood ratios for fibrinogen were, in the same time intervals, 26:1 (range 17-41) and 2:1 (range 0.5-3.9), respectively. It is concluded that radioiodinated Fragment El is a specific marker of thrombi in vivo: its uptake by fresh thrombi is better than that of labeled fibrinogen and, in contrast to radioiodinated fibrinogen, this fragment is incorporated into old thrombi as well.
INTRODUCTION
Deep vein thrombosis (DVT) ' is a frequent complication of many clinical syndromes, including fractured hip, major surgical procedures, stroke, and myocardial infarction; however, clinical symptoms are evident in only -50% of cases (1) . Current methods for detecting DVT are not entirely satisfactory. Contrast venography is reliable, but it is associated with a number of serious side-effects when conventional contrast medium is used (2) . Doppler ultrasound and impedance plethysmography are useful only in detecting occlusive thrombi in the thigh (2) ; they are of limited overall sensitivity, unless performed in combination with another test providing sensitivity in the calf, such as the '25I-fibrinogen uptake test (FUT) . Unfortunately, the FUT (3, 4) requires several days before a result is obtained, and a rapid diagnosis is desirable to decide a course of therapy. More rapid radionuclide tests, such as venography using radiolabeled particulates (5-7), may be performed to diagnose DVT, but the test is not useful below the knee and is also not reliable for providing images of thrombi, owing to the dependence upon nonspecific adhesion (7) . Specific agents such as "'Indium-labeled autologous platelets have been shown to localize in thrombi to permit imaging throughout the body (8-*11), but the test is not rapid: images are usually not obtained sooner than -24 h after injection due to the slow blood clearance of platelets. Thus, the existing noninvasive tests are either not adequately specific or are too slow.
There remains a need for a rapid, noninvasive, safe, sensitive, and specific test for the detection of DVT. Such a test is needed for the assessment not only of thrombotic disease in the lower extremities, but also thrombotic and embolic disease in the heart, brain, and lungs.
Fragment El, derived from plasmic digestion of crosslinked fibrin (12) , has unique binding properties. This dimeric molecule binds only to polymers of fibrin, such as are present in a thrombus, but it does not bind to fibrinogen, fibrin monomer, nor to any soluble plasma protein (13) . This specificity for the major component of venous thrombi makes Fragment El particularly interesting for development as a thrombus-localizing molecular marker.
In this study, Fragment El was isolated from human cross-linked fibrin, radiolabeled with isotopes of iodine, and tested for binding to fresh and aged thrombi. The specificity of Fragment El binding in yitro was assessed and followed by measurements of target-to.background uptake in thrombi in vivo. The uptake of radiolabeled fibrinogen in the same model has also been measured in order to compare these two thrombus-localizing agents.
METHODS
Preparation of Fragment El. The isolation and purification of human Fragment El was carried out as previously described (14) . Briefly, fibrinogen (obtained from citrated human plasma by glycine precipitation [15] ) was clotted with thrombin (bovine origin, Parke-Davis, Div. of Warner-Lambert, Inc., Morris Plains, NJ), in the presence of Factor XIIIa. The resulting cross-linked fibrin was digested with plasmin for 24 h at 370C, after which Trasylol (aprotinin, FBA Pharmaceuticals, New York; 250 units/ml final concentration) was added to stop the digestion. Gel chromatography on a 3.5 X 170-cm column of Sepharose CL-6B (Pharmacia Fine Chemicals, Piscataway, NJ) was used to separate the digestion products. The (DD)E complex, the main product of the digestion, was present in the first major protein peak. The complex was dissociated by treatment with an equal volume of 6 M urea, pH 5.5, at 370C for 1 h. A second passage through the same column resulted in the separation of Fragment El from Fragment DD. Fragment El was concentrated by ultrafiltration in a stirred cell with a PM 10 membrane of 10,000 mol wt cutoff (Amicon Corp., Lexington, MA), then dialyzed against 0.05 M Tris buffer containing 0.1 M NaCl, pH 7.0, and stored at -20'C. Tests used in monitoring the progress of the isolation procedure have been described in detail (12, 14) .
Polyacrylamide gel electrophoresis. Batches of Fragment El were analyzed in nondissociating medium in 9% Trisglycine gels according to the method of Davis (16) From these data, a thrombus-to-blood radioactivity ratio was calculated as an indication of the ability of an external detection system, such as a gamma camera, to detect the radioactivity associated with the thrombus in the face of the background radiation. The ratio was obtained using the following formula: Thrombus/blood ratio net counts in thrombus . weight of thrombus net counts in blood sample + weight of blood sample' Biodistribution of radioiodinated Fragment E1. The organ distribution of radioactivity following intravenous injection of radioiodinated Fragment E1 was determined in mice and pigs in order to gain some insight into the catabolic pathway and catabolic rate of the marker. In addition, the knowledge of the biodistribution is essential for later use in estimating radiation exposure to human subjects receiving the tracer for clinical diagnosis of thromboembolic disease. and were killed at 24 h postinjection. Tissues and fluids were sampled for counting. The whole organs were counted after dissection from mice. With the pigs, weighed representative samples of each organ were counted, and the whole organ was weighed to estimate the radioactive content of the whole organ. Similarly, representative samples of whole blood and bone were counted, and blood volume and whole bone mass were estimated to be 7 and 10% of body weight, respectively. For each animal, the total feces and urine excreted were counted. Because thyroid uptake of free radioiodide was so significant, an additional pair of pigs was studied after giving orally 2 drops potassium iodide solution (1 g/ml, PhilipsRoxane Laboratories, Inc., Columbus, OH), diluted with 10 ml of water, to attempt to block thyroid uptake. The pigs' dose of KI per unit of body weight was equal to that for a human (-3-4 mg KI/kg body wt).
RESULTS
Labeling yields. The efficiency of incorporation of radioiodine into Fragment El using the Iodogen method was 70±7% (mean+SD, n = 12). It was later found that addition of carrier iodide was not necessary to achieve these yields. The specific activities of '25I-Fragment El and "3'I-Fragment El were 2.0 and 1.77 mCi/ mg, respectively. The iodination level for these prep Table III . The Fragment El appeared to be removed by the liver, with maximum accumulation levels achieved at 10 min. The radioiodine label may be released due to the degradation of Fragment El by the liver, as the successive distribution of radioactivity resembled that of free iodide: uptake by thyroid gland, appearance in the gastrointestinal tract (especially the stomach), kidneys, and urine. In later studies in humans (Knight, L. C., unpublished observations), urine radioactivity was not precipitable with 10% trichloroacetic acid (TCA), suggesting nonprotein-bound radioiodide, and the fraction of blood plasma radioactivity precipitable with TCA decreased with time, suggesting that radioiodide liberated in the liver reappears in the blood.
Metabolism of radioiodinated Fragment El appeared to be slower in pigs than in mice. The 24-h pig values (Table IV) correspond to the 6-h mouse values. Partially blocking the thyroid appeared to allow excretion to proceed at a more rapid rate. This treatment was par- FIGURE 2 Incorporation of radiolabeled Fragment El (X) and fibrinogen (0) in vivo into thrombi of various ages. Thrombi were induced in jugular veins of young pigs, aged for the time shown on the horizontal axis, then both radiolabeled Fragment El and human fibrinogen were injected intravenously and the animal killed after 24 h. Each thrombus was removed along with a blood specimen and both were counted and weighed. The ratio of thrombus-toblood radioactivities is plotted on the vertical axis.
ticularly important for lowering of the remaining blood radioactivity from 6.9 to 2.9%, which would permit improved discrimination between thrombus and background radioactivities in vivo.
DISCUSSION
Development of specific molecular markers capable of binding to thrombi in vivo and transmitting this information to an external detector is the focus of our current efforts in the diagnosis of thrombotic and thromboembolic disease. It has been demonstrated in this work that Fragment El represents such a marker. Radioiodinated Fragment El is incorporated in vitro into both forming and preformed clots (Table II) . It is taken up in vivo by both fresh and aged thrombi (Fig.  2) ; this phenomenon is most likely associated with the (Fig. 2) ; the FUT is known to miss old thrombi (2) and that phenomenon was confirmed in this work. The values obtained here for thrombus-to-blood ratios of iodinated fibrinogen as a function of thrombus age correlated well with similar fibrinogen uptake studies in other animal models of thrombosis (11, 20 (25) , 6 of which are particularly susceptible to iodination (26) . The stability of radiolabeled Fragment El in vitro (Table I, Fig. 1 ) demonstrated that radioiodine is not being detached easily from the labeled protein. It is concluded that the fast rate of disappearance of radioactivity from the blood and appearance in the kidney and urine was dependent on rapid metabolism of Fragment El rather than on the release of radioiodine in the circulation (Tables III and   IV) . Because the liver radioactivity is transient, rapid catabolism of the labeled protein is the probable explanation for blood disappearance rather than the uptake of small aggregates, which would also be taken up by the liver, but would reside there longer. In addition, aggregates would not penetrate the polyacrylamide gels during electrophoresis and would remain near the top of the gel. Since this was not observed (Fig. 1) , the labeling procedure did not induce formation of aggregates of Fragment El.
The rapid catabolism of radioiodinated Fragment El and its affinity for fibrin polymers, in addition to a lack 2012 of binding to fibrinogen or fibrin monomer, constitute requisite properties of a molecular marker of thrombosis. The data presented in this work are encouraging and suggest the applicability of radiolabeled Fragment E1 for fast and specific detection and monitoring of thrombotic disease in humans.
